2026年2月13日,美国旧金山和中国苏州——信达生物制药集团(香港联交所股票代码:01801),一家致力于研发、生产和销售肿瘤、自身免疫、代谢、眼科等重大疾病领域创新药物的生物制药公司宣布,其自主研发的HER2单克隆抗体-喜树碱衍生物偶联物IBI354(HER2 ADC),用于一线治疗HER2阳性不可切除的局部晚期或转移性乳腺癌的关键III期临床研究(HeriCare-Breast01)完成中国...
Source Link2026年2月13日,美国旧金山和中国苏州——信达生物制药集团(香港联交所股票代码:01801),一家致力于研发、生产和销售肿瘤、自身免疫、代谢、眼科等重大疾病领域创新药物的生物制药公司宣布,其自主研发的HER2单克隆抗体-喜树碱衍生物偶联物IBI354(HER2 ADC),用于一线治疗HER2阳性不可切除的局部晚期或转移性乳腺癌的关键III期临床研究(HeriCare-Breast01)完成中国...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.